Salta al contenuto principale
Ricerc@Sapienza
Toggle navigation
Home
Login
Home
Persone
paolo.marchetti@uniroma1.it
Paolo Marchetti
Professore Ordinario
Struttura:
DIPARTIMENTO DI MEDICINA CLINICA E MOLECOLARE
E-mail:
paolo.marchetti@uniroma1.it
Pagina istituzionale corsi di laurea
Curriculum Sapienza
Pubblicazioni
Titolo
Pubblicato in
Anno
Commentary on "a case of paratesticular leiomyosarcoma successfully treated with orchiectomy and chemotherapy"
CANCER RESEARCH AND TREATMENT
2016
Pre-treatment evaluation of 5-fluorouracil degradation rate. association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort
ONCOTARGET
2016
CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy
THE EURASIAN JOURNAL OF MEDICINE
2016
Evolving treatments for advanced gastric cancer: appraisal of the survival trend
EXPERT REVIEW OF ANTICANCER THERAPY
2016
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies
EXPERT REVIEW OF VACCINES
2016
H2020 and beyond: skip discrepancy between theory and practice of personalized medicine. A position paper by the italian society of personalized medicine
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
2016
The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer
ANTI-CANCER DRUGS
2016
High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adoloscents and young adults
LUNG CANCER
2016
Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer
ONCOTARGET
2016
Degradation rate of 5-fluorouracil in metastatic colorectal cancer. A new predictive outcome biomarker?
PLOS ONE
2016
5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX
ANTI-CANCER DRUGS
2016
Neoadjuvant sequential docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab. The DECT trial
JOURNAL OF CELLULAR PHYSIOLOGY
2016
Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients
JOURNAL OF CANCER
2016
Exploring the Prognostic Role of Microsatellite Instability in Patients With Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis
CLINICAL COLORECTAL CANCER
2016
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients. A multicenter Italian experience
THE BREAST
2016
A rare case of palatin tonsillar metastasis from small cell lung cancer
TRANSLATIONAL LUNG CANCER RESEARCH
2016
High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art
DIGESTIVE AND LIVER DISEASE
2016
Re. "Awareness and consideration of malnutrition among oncologists: Insights from an exploratory survey"
NUTRITION
2016
Ethics in oncology: Principles and responsibilities declared in the Italian Ragusa statement
TUMORI
2016
Bevacizumab as first-line treatment in HER2-negative advanced breast cancer. Pros and cons
TUMORI
2016
« prima
< precedente
…
2
3
4
5
6
7
8
9
10
11
12
13
seguente ›
ultima »
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma